MEEPLUS

Meeplus is a South Korean biotechnology company specializing in the development of microbiome-based therapeutics and advanced cosmeceuticals. The company leverages its proprietary platform to identify and utilize beneficial microorganisms and their derivatives, such as exosomes, for medical and aesthetic applications. Their primary research focus includes treatments for alopecia (hair loss) and inflammatory skin conditions like atopic dermatitis. Meeplus integrates advanced microbial analysis with drug delivery technologies to create next-generation biopharmaceuticals and functional skincare products. The company's lead candidate, MP-101, utilizes microbiome-derived exosomes to stimulate hair follicle growth via the Wnt signaling pathway. By combining clinical research with aesthetic medicine, Meeplus aims to provide innovative solutions for regenerative dermatology.